[go: up one dir, main page]

WO2009057733A1 - Nouveau dérivé d'indole présentant une activité anti-angiogénique - Google Patents

Nouveau dérivé d'indole présentant une activité anti-angiogénique Download PDF

Info

Publication number
WO2009057733A1
WO2009057733A1 PCT/JP2008/069841 JP2008069841W WO2009057733A1 WO 2009057733 A1 WO2009057733 A1 WO 2009057733A1 JP 2008069841 W JP2008069841 W JP 2008069841W WO 2009057733 A1 WO2009057733 A1 WO 2009057733A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
novel indole
angiogenic activity
indole derivative
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/069841
Other languages
English (en)
Japanese (ja)
Inventor
Takahiro Honda
Hiroyuki Mogi
Hiroyuki Aono
Masakazu Ban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of WO2009057733A1 publication Critical patent/WO2009057733A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne l'étude de la synthèse de nouveaux dérivés d'indole et concerne également l'application des composés à des fins médicales. Par conséquent, l'invention concerne un composé représenté par la formule (I) ou un sel de celui-ci [dans la formule, X représente O, S ou N-R4 ; R1 représente un groupe aryle, un groupe aromatique hétérocyclique ou des éléments analogues ; R2 représente un groupe aryle, un groupe aromatique hétérocyclique ou des éléments analogues ; R3 représente un atome d'hydrogène, un groupe alkyle, un groupe alkylcarbonyle ou des éléments analogues ; et R4 représente un atome d'hydrogène, un groupe alkyle ou des éléments analogues. (I)
PCT/JP2008/069841 2007-10-31 2008-10-31 Nouveau dérivé d'indole présentant une activité anti-angiogénique Ceased WO2009057733A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-282727 2007-10-31
JP2007282727 2007-10-31
JP2008054482 2008-03-05
JP2008-054482 2008-03-05

Publications (1)

Publication Number Publication Date
WO2009057733A1 true WO2009057733A1 (fr) 2009-05-07

Family

ID=40591113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069841 Ceased WO2009057733A1 (fr) 2007-10-31 2008-10-31 Nouveau dérivé d'indole présentant une activité anti-angiogénique

Country Status (2)

Country Link
JP (1) JP2009235057A (fr)
WO (1) WO2009057733A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015022926A1 (fr) * 2013-08-12 2015-02-19 大鵬薬品工業株式会社 Nouveau composé pyrimidine fusionnée ou son sel
WO2016121953A1 (fr) * 2015-01-30 2016-08-04 大鵬薬品工業株式会社 Agent prophylactique et/ou thérapeutique destiné à des maladies immunitaires
CN110938027A (zh) * 2019-11-20 2020-03-31 天津大学 一种吲哚类衍生物的合成方法
EP4076444A4 (fr) * 2019-12-18 2024-01-10 Merck Sharp & Dohme LLC Dérivés d'indazole et leurs méthodes d'utilisation dans le traitement de l'herpès virus

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102667829A (zh) 2009-10-09 2012-09-12 日本电气株式会社 信息管理装置、数据处理方法及计算机程序

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502292A (ja) * 1995-06-30 2001-02-20 ザイモジェネティクス，インコーポレイティド Ｐｄｇｆアンタゴニストとしての４−〔２−（ｎ−２−カルボキサミドインドール）アミノエチル〕ベンゼンスルホンアミドまたはスルホニル尿素
JP2002167376A (ja) * 2000-11-30 2002-06-11 Mercian Corp 血管内皮細胞増殖因子発現抑制作用を有するインドール誘導体及びその用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502292A (ja) * 1995-06-30 2001-02-20 ザイモジェネティクス，インコーポレイティド Ｐｄｇｆアンタゴニストとしての４−〔２−（ｎ−２−カルボキサミドインドール）アミノエチル〕ベンゼンスルホンアミドまたはスルホニル尿素
JP2002167376A (ja) * 2000-11-30 2002-06-11 Mercian Corp 血管内皮細胞増殖因子発現抑制作用を有するインドール誘導体及びその用途

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105452257B (zh) * 2013-08-12 2017-09-05 大鹏药品工业株式会社 新型稠合嘧啶化合物或其盐
CN105452257A (zh) * 2013-08-12 2016-03-30 大鹏药品工业株式会社 新型稠合嘧啶化合物或其盐
RU2666349C2 (ru) * 2013-08-12 2018-09-07 Тайхо Фармасьютикал Ко., Лтд. Новое конденсированное пиримидиновое соединение или его соль
US9580432B2 (en) 2013-08-12 2017-02-28 Taiho Pharmaceutical Co., Ltd. Fused pyrimidine compound or salt thereof
JPWO2015022926A1 (ja) * 2013-08-12 2017-03-02 大鵬薬品工業株式会社 新規な縮合ピリミジン化合物又はその塩
WO2015022926A1 (fr) * 2013-08-12 2015-02-19 大鵬薬品工業株式会社 Nouveau composé pyrimidine fusionnée ou son sel
US9782412B2 (en) 2015-01-30 2017-10-10 Taiho Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent of immune disease
JPWO2016121953A1 (ja) * 2015-01-30 2017-04-27 大鵬薬品工業株式会社 免疫疾患の予防及び／又は治療剤
RU2705154C2 (ru) * 2015-01-30 2019-11-05 Тайхо Фармасьютикал Ко., Лтд. Средство для профилактики и/или терапии иммунного заболевания
WO2016121953A1 (fr) * 2015-01-30 2016-08-04 大鵬薬品工業株式会社 Agent prophylactique et/ou thérapeutique destiné à des maladies immunitaires
CN113768935A (zh) * 2015-01-30 2021-12-10 大鹏药品工业株式会社 免疫疾病的预防剂和/或治疗剂
CN113768935B (zh) * 2015-01-30 2024-10-01 大鹏药品工业株式会社 免疫疾病的预防剂和/或治疗剂
CN110938027A (zh) * 2019-11-20 2020-03-31 天津大学 一种吲哚类衍生物的合成方法
CN110938027B (zh) * 2019-11-20 2022-11-25 河北凯诺中星科技有限公司 一种吲哚类衍生物的合成方法
EP4076444A4 (fr) * 2019-12-18 2024-01-10 Merck Sharp & Dohme LLC Dérivés d'indazole et leurs méthodes d'utilisation dans le traitement de l'herpès virus

Also Published As

Publication number Publication date
JP2009235057A (ja) 2009-10-15

Similar Documents

Publication Publication Date Title
WO2008111441A1 (fr) Composition pharmaceutique
WO2008108378A3 (fr) Dérivé bicyclique d'oxomorpholine
WO2008114817A1 (fr) Nouveau composé d'adénine
NO20084350L (no) Heterocykliske amider til anvendelse som farmasoytika
UA105185C2 (uk) Піроли
WO2008087933A1 (fr) Nouveau dérivé d'indole ayant une activité inhibitrice sur la iκb kinase β
JO3259B1 (ar) مشتق دائري مغاير ملتحم واستخدامه
WO2008126901A1 (fr) Composé hétérocyclique contenant de l'azote et composition pharmaceutique le contenant
WO2008108380A3 (fr) Composés de pyrrole
MY148703A (en) Polycyclic cinnamide derivatives
MY177250A (en) Novel nicotinamide derivative or salt thereof
WO2011004162A3 (fr) Composés utilisés en tant que médicaments
WO2008108386A1 (fr) Composition pharmaceutique
WO2008146871A1 (fr) Nouveau dérivé de 1,2,3,4-tétrahydroquinoxaline qui a, comme substituant, un groupe phényle dans lequel est introduite une structure d'ester d'acide sulfonique ou une structure d'amide d'acide sulfonique et qui possède une activité de liaison aux récepteurs des glucocorticoïdes
WO2009069736A1 (fr) Composé azoté
WO2008114812A1 (fr) Inhibiteur de jak
TW200745034A (en) New compounds
WO2008136444A1 (fr) Dérivé hétérocyclique fusionné
WO2009154754A3 (fr) Synthèse de dérivés de morpholine deutérés
MX2010001566A (es) Derivado de aminopirazolamida.
WO2009057733A1 (fr) Nouveau dérivé d'indole présentant une activité anti-angiogénique
WO2008153042A1 (fr) Agent antitumoral
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
WO2008136378A1 (fr) Nouveau dérivé de sulfonamide et son sel
MY161992A (en) Novel tetrahydroisoquinoline derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08843901

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08843901

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP